Extended Data Fig. 8: αPD-1 or ABT263 treatments improve NASH pathologies.
From: Blocking PD-L1–PD-1 improves senescence surveillance and ageing phenotypes
a, The activation and infiltration of hepatic CD8+ T cells analyzed by FACS from wild type mice fed with normal diet (Normal) or L-amino acid diet with 60 kcal % fat, 0.1 % methionine, and no added choline (CDA-HFD) for 10 weeks combined with αPD-1 or ABT263 treatments as in Fig. 4e. Gating strategy was shown in the right panel. (Normal placebo: n = 6, Normal αPD-1: n = 6, Normal ABT263: n = 5, CDA-HFD placebo: n = 6, CDA-HFD αPD-1: n = 6, CDA-HFD ABT263: n = 6) b, The serum levels of AST, ALT, and LDH from the mice as in a. (Normal placebo: n = 6, Normal αPD-1: n = 6, Normal ABT263: n = 5, CDA-HFD placebo: n = 6, CDA-HFD αPD-1: n = 6, CDA-HFD ABT263: n = 6) c, The Sirius red staining of livers from the mice as in a. The representative images were shown in upper panels. The percentage of red area (collagen area) in each filed was quantified and described as the hepatic fibrogenesis. Scale bar: 100 μm (n = 6 for each group) d, Body weights and serum total cholesterol (T-CHO) from the mice as in a. (n = 6 for each group) Data are presented as means ± SEM of three or more independent experiments. Two-way ANOVA with Sidak’s test was performed. **P < 0.01, ****P < 0.0001. The precise p-values were described in Methods.
